Published in Medicine and Law Weekly, March 11th, 2005
Under the terms of the license agreement, Benitec has exclusive rights to develop RNA interference (RNAi)-based drugs for diabetes, obesity, and related disorders. Benitec and Garvan have also entered into discussions for a research collaboration to develop these novel therapies.
Both the licensed intellectual property and the proposed research collaboration focus on the c-Cbl gene (pronounced "c-cybil") as a drug target for diabetes and obesity. The Garvan Institute recently made international headlines with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.